Thomson Reuters, a distinguished brokerage company, has placed a 52-week price target of $20.00 on Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) shares after it surveyed top market analysts. Calculating estimated earnings after taking into consideration different elements, it is predicted to come at $1.02 for the next fiscal and $N/A for underway quarter.
Analysts take into account the price to earnings ratio to estimate the firm’s valuation. This ratio, which is also called as the P/E ratio evaluates the company on relative expense factor. The formula to calculate ratio is stock’s latest price/ per share earnings. The P/E ratio of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) stands at 14.87.
Analysts also work out Price/Earnings Growth ratio in an attempt to estimate the valuation of a firm. This ratio commonly known as the PEG ratio implies the stock’s valuation compared to earnings growth potential. Investors look to invest in the stocks with a lower PEG ratio. For Enanta Pharmaceuticals, Inc., the PEG ratio for coming 3-5 years is 0.00.
The technical analysis highlights that Enanta Pharmaceuticals, Inc. current is trading $-0.00 points away or -0.00% from its 50-day moving average of $22.49. Further it is trading $-3.13 or -12.23% away its 200-day moving average of $25.62.
The 52-week high of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) was $43.08 while lowest point recorded in 52-week was $16.75. It implies if stock price makes a movement of over $-20.59, it will record a new 52-week high. In the case of +34.27% drop, it will touch a new 52-week low.
1 Chart Pattern Every Investor Should Know